Literature DB >> 382941

Interferons: rationale for clinical trials in neoplastic disease.

E C Borden.   

Abstract

Interferons, cell glycoproteins synthesized in response to viral infections and various nonviral inducers, have proved therapeutically effective for viral infections in experimental models and in humans. Current evidence suggests interferons may also prove effective as antitumor agents in humans. Potent effects on cellular function result from interferons. Cell surface structure and enzyme levels are altered. Immunologic responses thought to be important in tumor immunity are augmented. Interferons have antiproliferative effects on the replication of normal and neoplastic cells. Interferons are effective in animals against tumors of both viral and nonviral origin. Clinical trials in cancer have been limited by the availability and cost of human interferons. However, results in small numbers of patients have been encouraging. This paper review experimental and clinical findings regarding the rationale for use of interferons in neoplastic disease.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 382941     DOI: 10.7326/0003-4819-91-3-472

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  14 in total

1.  A toxicity study of recombinant interferon-gamma given by intravenous infusion to patients with advanced cancer.

Authors:  K Sriskandan; P Garner; J Watkinson; K W Pettingale; D Brinkley; F M Calman; D E Tee
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Long-term influence of adjuvant therapy on natural killer cell activity in breast cancer.

Authors:  E Tichatschek; C C Zielinski; C Müller; P Sevelda; E Kubista; K Czerwenka; J Spona; H Wolf; M M Eibl
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

3.  The toxicity of recombinant human interleukin-2 in rats following intravenous infusion.

Authors:  Y L Matory; A E Chang; E H Lipford; R Braziel; C L Hyatt; S A Rosenberg
Journal:  J Natl Med Assoc       Date:  1987-05       Impact factor: 1.798

Review 4.  The interferon renaissance: molecular aspects of induction and action.

Authors:  J Gordon; M A Minks
Journal:  Microbiol Rev       Date:  1981-06

5.  Multiple biological activities of homogeneous human alpha interferon.

Authors:  A M Attallah; K Zoon; T Folks; J Huntington; T J Yeatman
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

6.  Phase I clinical trial of intralesional or intraventricular leukocyte interferon for intracranial malignancies.

Authors:  E A Obbens; L G Feun; M E Leavens; N Savaraj; D J Stewart; J U Gutterman
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

7.  Intratumoural and intraventricular human lymphoblastoid alpha interferon (HLBI) for treatment of glioblastoma multiforme.

Authors:  R Martínez; J Vaquero; J Ramiro; F García Salazar; S De Oya
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

8.  Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.

Authors:  E E Vokes; S M O'Brien; N J Vogelzang; R L Schilsky; M J Ratain
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Activity of human leukocyte interferon in a human tumor cloning system.

Authors:  D D Von Hoff; J Gutterman; B Portnoy; C A Coltman
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  Escalating doses of interferon alpha-2A with cisplatin and concomitant radiotherapy: a phase I study.

Authors:  E E Vokes; D J Haraf; P C Hoffman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.